Latest News
- October 4, 2016
- LAUNCH OF URITOS TABLETS FOR OVERACTIVE BLADDER IN THAILAND
- September 28, 2016
- MSD K.K. receives manufacturing and marketing approval for DESALEX Tablets 5mg for treatment of allergic diseases
- September 15, 2016
- MSD and Kyorin Sign Agreement on Co-Promotion of Therapeutic Agent for Allergic Rhinitis, NASONEX Nasal
- September 1, 2016
- Release of Montelukast tablets 10mg「KM」, Montelukast tablets 5mg「KM」
- July 29, 2016
- Consolidated Financial Results (For the First Quarter Ended June 30,2016)- Supplementary Information
- July 29, 2016
- Summary of Consolidated Financial Results (For the First Quarter Ended June 30, 2016) [Japanese Standard]
- June 20, 2016
- NHI Drug Price Listing and Release of Montelukast tablets 10mg「KM」, Montelukast tablets 5mg「KM」
- May 25, 2016
- MSD's investigational antiallergic agent desloratadine to be exclusively marketed by Kyorin
- May 12, 2016
- Supplementary information (May 12, 2016)
- March 30, 2016
- Kyorin and Kissei signed an Agreement for Co-Development and Co-Marketing of KRP-114V
- February 3, 2016
- Summary of Consolidated Financial Results (For the third Quarter Ended Dec 31,2015)[Japanese Standard]
- February 3, 2016
- Consolidated Financial Results (For the third Quarter Ended Dec 31,2015)- Supplementary Information
- February 3, 2016
- Revision of Consolidated Financial Forecasts
- February 3, 2016
- Termination of License Concerning COPD Therapeutic Drug KRP-AB1102F
- December 11, 2015
- Release of KIPRES OD Tablets 10mg, a treatment for bronchial asthma and allergic rhinitis
- December 11, 2015
- NHI Drug Price Listing of PENTASA Granules 94%, a treatment for Ulcerative Colitis and Crohn's Disease
- November 5, 2015
- KYORIN Pharmaceutical and PeptiDream Reach Agreement for Peptide Discovery Collaboration
- November 5, 2015
- Consolidated Financial Results (For the second Quarter Ended Sep 30,2015)- Supplementary Information
- November 5, 2015
- Summary of Consolidated Financial Results (For the second Quarter Ended Sep 30,2015)[Japanese Standard]
- October 15, 2015
- MSD Submits New Drug Application for Antiallergic Agent, Desloratadine to be Co-marketed with Kyorin
- August 31, 2015
- KYORIN Pharmaceutical and Synmosa Biopharma Corporation Sign License Agreement of Imidafenacin in Taiwan
- August 17, 2015
- Approval received for PENTASA Granules 94%, a treatment for Ulcerative Colitis and Crohn's Disease
- August 17, 2015
- Approval received for KIPRES OD Tablets 10mg, a treatment for bronchial asthma and allergic rhinitis
- July 30, 2015
- Summary of Consolidated Financial Results (For the First Quarter Ended June 30,2015)[Japanese Standard]
- July 30, 2015
- Consolidated Financial Results (For the First Quarter Ended June 30,2015)- Supplementary Information
- May 20, 2015
- Release of Eklira Genuair, a treatment for COPD
- May 13, 2015
- Summary of Consolidated Financial Results (For the fiscal year ended March 31, 2015) [Japanese Standard]
- March 26, 2015
- Genuair, a dry powder inhaler for COPD treatment, selected for iF UNIVERSAL DESIGN award for 2015
- March 26, 2015
- Approval received for Eklira Genuair, a treatment for COPD
- February 2, 2015
- Summary of Consolidated Financial Results (For the Third Quarter Ended Dec 31,2014)[Japanese Standard]
- February 2, 2015
- Consolidated Financial Results (For the Third Quarter Ended Dec 31,2014)- Supplementary Information
- December 1, 2014
- Release of Flutiform® 50 Aerosol - 120 inhalations, Flutiform® 125 Aerosol - 120 inhalations , a combination drug for asthma treatment
- November 27, 2014
- Signing of Co-Marketing Agreement on Investigational Antiallergic Agent, Desloratadine for Japan
- November 4, 2014
- Summary of consolidated financial results (November 4, 2014)
- November 4, 2014
- Consolidated Financial Results (For the Second Quarter Ended september 30,2014)- Supplementary Information
- September 10, 2014
- EISAI AND KYORIN ENTER INTO AGREEMENT CONCERNING COMPOUND LIBRARY USE FOR THE DEVELOPMENT OF NEW ANTIBACTERIAL AGENTS
- July 29, 2014
- Summary of Consolidated Financial Results (For the First Quarter Ended June 30, 2014) [Japanese Standard]
- July 22, 2014
- Kyorin signed a License Agreement with Merck on Vibegron for Overactive Bladder in Japan